2012
DOI: 10.4103/1947-2714.103312
|View full text |Cite
|
Sign up to set email alerts
|

Newer antibacterials in therapy and clinical trial

Abstract: In order to deal with the rising problem of antibiotic resistance, newer antibacterials are being discovered and added to existing pool. Since the year 2000, however, only four new classes of antibacterials have been discovered. These include the oxazolidinones, glycolipopeptides, glycolipodepepsipeptide and pleuromutilins. Newer drugs were added to existing classes of antibiotics, such as streptogramins, quinolones, beta-lactam antibiotics, and macrolide-, tetracycline- and trimethoprim-related drugs. Most of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0

Year Published

2012
2012
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 37 publications
0
8
0
Order By: Relevance
“…[42] The strategies for limiting or modifying antibiotic use are needed to control resistance growth and to improve the rational use of antibiotics. [43] The seven strategies to prevent antibiotic resistance that were suggested by Kollef in 2005[44] are as follows: (1) Establishment of a formal protocol and guidelines, (2) Hospital formulary restrictions, (3) Use of narrow spectrum antibiotics when supported by clinical situation and culture data, (4) Combination antibiotic therapy, (5) Shorter courses of antibiotic treatment, (6) Antibiotic heterogeneity, and (7) Optimization of pharmacokinetic/pharmacodynamic principles.…”
Section: Discussionmentioning
confidence: 99%
“…[42] The strategies for limiting or modifying antibiotic use are needed to control resistance growth and to improve the rational use of antibiotics. [43] The seven strategies to prevent antibiotic resistance that were suggested by Kollef in 2005[44] are as follows: (1) Establishment of a formal protocol and guidelines, (2) Hospital formulary restrictions, (3) Use of narrow spectrum antibiotics when supported by clinical situation and culture data, (4) Combination antibiotic therapy, (5) Shorter courses of antibiotic treatment, (6) Antibiotic heterogeneity, and (7) Optimization of pharmacokinetic/pharmacodynamic principles.…”
Section: Discussionmentioning
confidence: 99%
“…The process of discovering newer antibiotics is a lengthy one and requires a lot of financial resources. [14] Hence, it is important to have a scientific basis while prescribing antibiotics and this article aims to standardize the use of proper antibiotics in adenoid infection through culture studies.…”
Section: Discussionmentioning
confidence: 99%
“…The barriers that prevent facile transfer of vanA resistance into S. aureus are not well understood, and there is concern that these barriers may be overcome with continued evolution. While there is interest in substrate binders as a class, none of the ones that recognize the sugar pyrophosphate portion of Lipid II have been developed for clinical use, although ramoplanin is in clinical trials (Paknikar and Narayana 2012). As with vancomycin, high level resistance to ramoplanin does not develop spontaneously.…”
Section: Antibiotics Targeting the Cell Envelopementioning
confidence: 99%